ArticleApoptosis : an international journal on programmed cell death2026
Progenitor CD8
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Machine learning-derived mast cell-associated angiogenesis features can serve as prognostic targets for clear cell renal cell carcinoma.Translational andrology and urology · 2026Article
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
- Radiotherapy for overcoming immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma.Frontiers in immunology · 2026Review
- Advances and challenges in immunotherapy for advanced esophageal squamous cell carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite the crucial role of antigen presentation in immune checkpoint inhibitor (ICI) efficacy, its contribution and the mechanism in esophageal squamous cell carcinoma (ESCC) remain unclear, representing a key knowledge gap in overcoming immune escape in its immunotherapy. This study explores how tumor antigen presentation and intercellular interactions in the tumor microenvironment (TME) drive ICI resistance using single-cell RNA sequencing (scRNA-seq). Publicly available scRNA-seq data from 24 ESCC patients treated with chemotherapy and ICIs were analyzed. Cell clustering, transcription factor regulation, cell-cell communication analysis, and KEGG/GO enrichment analyses were used to examine malignant cell heterogeneity, the relationship between antigen-presenting cells and ICI responses, and cell-cell interactions influencing anti-tumor response. Spatial relationships were validated through multiplex immunofluorescence. Malignant cells were classified by enrichment analyses into cNMF_1, cNMF_2, cNMF_3, and cNMF_4, with cNMF_4 showing antigen-presenting traits. Based on ICI response groups, cell-cell communication analysis revealed that in poor responders, the antigen presentation ability of tumors induced by treatment was enhanced, and mainly enriched in the MHC-I pathway. The crosstalk between Progenitor CD8
Indexed as
Identifiers
41524793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.